GlassScriptPhysician profile
Jared Williams Atkinson
NPI 1629424114
$1,175.35
in general payments reported to CMS, 2019-2025
14 companies · $14.32 in 2025
The $14.32 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $101 · 2022: $121 · 2023: $868 · 2024: $70.93 · 2025: $14.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $953.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $305.64 | 2022-2023 | Vraylar |
| Neurocrine Biosciences, INC. | $139.70 | 2022-2024 | Ingrezza |
| Alkermes, INC. | $127.92 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $115.36 | 2023-2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $90.00 | 2021-2023 | Invega Sustenna, Invega Trinza |
| Takeda Pharmaceuticals U.S.A., INC. | $78.88 | 2022-2023 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $61.85 | 2023 | Austedo |
| Otsuka America Pharmaceutical, INC. | $61.18 | 2021-2024 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $45.49 | 2023 | Rexulti |
| Corium, LLC | $38.90 | 2023 | Azstarys |
| Axsome Therapeutics, INC. | $36.79 | 2022-2023 | Auvelity |
| Bausch Health US, LLC | $33.02 | 2022-2023 | Aplenzin |
| Sunovion Pharmaceuticals INC. | $21.97 | 2021 | |
| Bioxcel Therapeutics, INC. | $18.65 | 2023 | Igalmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Atkinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.